Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?

Норадренергические методы лечения нейродегенеративных заболеваний: от симптоматической терапии к терапии, модифицирующей течение заболевания?
James Benedict Rowe, Claire O’Callaghan, Robert Durcan
2025-01-01

disease-modifying therapyglymphatic systemlocus coeruleus degenerationneuroinflammationnoradrenergic therapies
Abstract A feature shared by many different neurodegenerative diseases is early pathology and degeneration of the pontine locus coeruleus. The human locus coeruleus contains about 50 000 neurons and is the primary source of the neurotransmitter noradrenaline. We propose the hypothesis that noradrenergic drugs can have broad, transdiagnostic benefit in slowing or preventing the progression of neurodegenerative diseases. There are direct noradrenergic anti-inflammatory effects in vivo, with microglia and astrocytes regulated by adrenoreceptors, and noradrenergic influences on glymphatics. Noradrenaline loss is associated with a pro-inflammatory state, promoting further neurodegeneration. Noradrenergic neuron loss is associated with worsening of both amyloid and tau deposition in animal models. There may be indirect survival benefits arising from alleviating the prognostically detrimental features of apathy and impulsivity, and noradrenergic influences on other neurotransmitters. The evidence base we set out supports the need for clinical trials of noradrenergic treatments for disease-modification.
1
Early pathology and degeneration of the locus coeruleus are shared features across many neurodegenerative diseases.
2
Noradrenaline directly regulates microglia, astrocytes, and glymphatic function, producing potential anti-inflammatory and clearance-related effects.
3
Noradrenaline loss promotes a pro-inflammatory state and is associated with worsening amyloid and tau deposition in animal models.
4
Noradrenergic drugs are hypothesized to provide broad, transdiagnostic benefits by slowing or preventing neurodegenerative progression.
5
The evidence supports conducting clinical trials to test noradrenergic treatments as potential disease-modifying therapies.

Noradrenergic systems and therapies in neurodegenerative diseases, including the pontine locus coeruleus and its noradrenergic neurons

The disease-modifying effects and mechanisms of noradrenergic therapies, including anti-inflammatory, glymphatic, protein-deposition, and symptom-mediated influences on neurodegeneration

Publication Details
Publication Date
2025-01-01
Journal
Publisher
ISSN
Cited by
14
Access Type
Author Information
Authors
James Benedict Rowe
Claire O’Callaghan
Robert Durcan
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%